Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05724953
Other study ID # D4089-P
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 1, 2023
Est. completion date May 30, 2025

Study information

Verified date October 2023
Source VA Office of Research and Development
Contact David Kimhy, PhD
Phone (718) 584-9000
Email David.Kimhy@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Suicide rates among Veterans with Serious Mental Illness (SMI) are intractably high, representing a serious public health concern and a critical target for interventions. Yet, at present available treatments offer modest benefits. Thus, there remains an urgent need to identify novel approaches to address suicide risk in this population. Previous reports have linked suicide risk with poor social functioning. Emerging evidence from basic affective neuroscience research has indicated that effective social functioning is contingent on intact emotion awareness. Consistent with these findings, individuals with SMI at risk of suicide display social functioning difficulties along with poor emotion awareness (i.e., alexithymia). Employing a proof-of-concept design, the aim of the present study is to test the feasibility and acceptability of a novel, blended psychoeducation and digital mHealth (mobile health) intervention with smartphones designed to target alexithymia and poor social functioning to reduce suicide risk in Veterans with SMI.


Description:

Suicide rates among veterans with Serious Mental Illness (SMI) are intractably high. Yet, at present available treatments offer only minimal to limited benefits to ameliorate this risk, despite a VA-wide implementation of enriched suicide prevention services and the availability of a national suicide hotline. This dire state represents a serious public health concern and a critical target for interventions. In response to this state, the Rehabilitation Research & Development Service (RR&D)'s Behavioral Health & Social Reintegration Program has highlighted the need for development of suicide prevention interventions that enhance social reintegration, functional outcomes, and improve overall participation in society. Germane to social functioning, extensive evidence from basic affective neuroscience research indicates that effective social functioning requires intact emotion awareness. Specifically, emotions are posited to provide crucial information about the significance of social situations and help to guide potential actions to be taken to navigate such situations. Negative emotional experiences in particular have critical informational value in signaling the need to adjust one's current state or activity. As different emotions may call for the use of distinct response strategies, lack of or reduced awareness of experienced feelings may make it difficult for individuals to choose response strategies for dealing effectively with social situations, resulting in poor social functioning. Consistent with these findings, recent reports indicate alexithymia, a transdiagnostic clinical syndrome characterized by poor emotion awareness, to be highly prevalent among veteran and civilians with SMI, with a recent large systematic review and meta-analysis indicating alexithymia predicting suicide ideation and behavior. Relatedly, previous reports indicate alexithymia has a detrimental impact on treatment outcomes. Altogether, these findings suggest alexithymia may play a key role in impacting suicide risk and treatment response in Veterans. Yet, despite its pervasiveness, chronic presentation, link to SMI and poor social functioning, and impact on clinical outcomes, the putative impact of alexithymia on suicide risk has not been investigated in Veterans with SMI at risk of suicide. Building on these findings, the goal of this project is to test the feasibility and acceptability of a novel, blended psychoeducation and digital mHealth (mobile health) intervention designed to target alexithymia and poor social functioning to reduce suicide risk in Veterans with SMI. Employing a proof-of-concept design, 40 participants will attend weekly group psychoeducation sessions targeting emotion awareness and social functioning along with an innovative mHealth emotion awareness skill training via smartphone to reduce alexithymia, enhance social functioning, and reduce suicide risk. Results from the present study will provide comprehensive characterization of suicide risk among Veterans with SMI, provide preliminary acceptability and feasibility data, and will inform the development of a randomized clinical trial to test the efficacy of the intervention to ameliorate suicide risk in this population.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date May 30, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - a DSM-V diagnosis of PTSD - bipolar disorder - MDD - schizophrenia - at risk of suicide(Columbia Suicide Severity Rating Scale - C-SSRS 3 or a suicide attempt in the past year) - limited emotion awareness (Toronto Alexithymia Scale; TAS-20 52) - can understand all the study's risks and benefits Exclusion Criteria: - have medical/neurological conditions that could interfere with study participation - enrolled in another treatment study - unable/unwilling to provide a verifiable contact for emergency purposes

Study Design


Intervention

Behavioral:
Affective Awareness
Intervention involving psychoeducation and daily emotion awareness practices

Locations

Country Name City State
United States James J. Peters VA Medical Center, Bronx, NY Bronx New York

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other MIRECC-GAF Change A rater-based index of occupational and social functioning. Baseline, 6 weeks, 8 weeks.
Other World Health Organization Quality of Life - Brief (WHOQOL-BREF) Change A self-report scale indexing quality of life. Baseline, 6 weeks, 8 weeks.
Other Emotion Regulation Questionnaire (ERQ) Change A self-report scale indexing emotion regulation. Baseline, 6 weeks, 8 weeks.
Other Beck Depression Inventory (BDI) Change A self-report scale indexing depressed mood. Baseline, 6 weeks, 8 weeks.
Other Beck Anxiety Inventory (BAI) Change A self-report scale indexing anxiety. Baseline, 6 weeks, 8 weeks.
Other Structured Clinical Interview for DSM-V Axis I (SCID-I) A rater-based clinical interview used to establish psychiatric diagnoses. Baseline.
Other Clinician-Administered PTSD Scale for DSM-V (CAPS-V) A rater-based clinical interview used to assess trauma. Baseline.
Other Childhood Trauma Questionnaire (CTQ) A self-report scale indexing childhood trauma. Baseline.
Primary Columbia Suicide Severity Rating Scale (C-SSRS) Change A semi-structured interview indexing suicide risk and related domains including ideation, severity, intensity, behavior, and lethality. Baseline, 6 weeks, 8 weeks.
Primary Toronto Alexithymia Scale (TAS-20) Change A self-report scale indexing difficulty identifying, difficulty describing feelings, and externally oriented thinking. Baseline, 6 weeks, 8 weeks.
Primary Provision of Social Relations Scale (PSRS) Change A self-report scale indexing relationship with family and friends. Baseline, 6 weeks, 8 weeks.
Secondary Emotion Granularity Index Change An smartphone-based index of emotion granularity based on reports of emotions during daily functioning. Baseline, 6 weeks, 8 weeks.
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A